预约演示
更新于：2025-08-04
Fosphenytoin Sodium
磷苯妥英钠
更新于：2025-08-04
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C16H15N2Na2O6P |
InChIKeyCKBXTXIAQHEVAB-UHFFFAOYSA-N |
CAS号92134-98-0 |
关联
23
项与 磷苯妥英钠 相关的临床试验CTR20251674
磷苯妥英钠注射液在中国健康受试者中单次肌肉注射给药的、随机、开放、两序列、两周期、交叉生物等效性试验
CTR20250230
磷苯妥英钠注射液（T）、磷苯妥英钠注射液（R1）和苯妥英钠注射液（R2）在健康受试者中静脉输注给药的生物等效性试验
CTRI/2024/12/077706
Efficacy, Safety, and Tolerability of Intramuscular Versus Intravenous Fosphenytoin for Pediatric Status Epilepticus - A Randomised-Controlled, Open-label, Non-inferiority Trial
100 项与 磷苯妥英钠 相关的临床结果
登录后查看更多信息
100 项与 磷苯妥英钠 相关的转化医学
登录后查看更多信息
100 项与 磷苯妥英钠 相关的专利（医药）
登录后查看更多信息
624
项与 磷苯妥英钠 相关的文献（医药）2025-08-01EPILEPSY RESEARCH
Adequate and inadequate dosing of anti-seizure medications in status epilepticus
Article
作者: Smith, Melissa ; Schrader, Susan
BACKGROUND:
Status epilepticus (SE) is defined as five or more minutes of continuous seizures or two or more discrete seizures with incomplete recovery of consciousness.1 The incidence of SE in the United States ranges from 18.3 to 41 per 100,000 patients per year2. Reviews of SE clinical literature demonstrate that 70-75 % of patients did not receive an adequate dose of benzodiazepine according to clinical guidelines. Underdosing of benzodiazepines increases the risk of refractory SE and unfavorable outcomes.8-9 METHODS: This single center retrospective cohort study evaluated the dosing of benzodiazepines and other anti-seizure medications in adult patients with SE. The primary outcomes were incidence of breakthrough seizures in patients with appropriate dosing benzodiazepines compared to inappropriate dosing of benzodiazepines within 24 h of the first dose and incidence of breakthrough seizures in patients with appropriate loading dose of maintenance anti-seizure medication compared to inappropriate loading dose of anti-seizure medication within 24 h of the first dose.
RESULTS:
Thirty-eight patients received adequate benzodiazepine dosing compared to 155 with inadequate dosing. Eighty-seven percent of patients with adequate dosing of benzodiazepine experienced a breakthrough seizure compared to 84 % of patients with inadequate dosing (p = 0.62). Sixty-three percent of patients with adequate dosing of benzodiazepines required first non-benzodiazepine anti-seizure medication compared to 63 % of patients with inadequate dosing (p = 0.76). Breakthrough seizures within 24 h after the first load of non-benzodiazepine anti-seizure medication occurred in 21 % of patients in the adequate dosing group compared to 28 % in the inadequate dosing group (p = 0.73).
CONCLUSION:
While benzodiazepines and rescue anti-seizure medications are frequently underdosed in patients with status epilepticus, there was no difference in recurrent seizures comparted to those with adequate dosing.
2025-06-01MOLECULAR DIVERSITY
Exploring potential biomarkers and lead molecules in gastric cancer by network biology, drug repurposing and virtual screening strategies
Article
作者: Vyas, Renu ; Saha, Sagarika ; Vijayasarathi, Durairaj ; Bapat, Sanket
Gastric cancer poses a significant global health challenge, necessitating innovative approaches for biomarker discovery and therapeutic intervention. This study employs a multifaceted strategy integrating network biology, drug repurposing, and virtual screening to elucidate and expand the molecular landscape of gastric cancer. We identified and prioritized key genes implicated in gastric cancer by utilizing data from diverse databases and text-mining techniques. Network analysis underscored intricate gene interactions, emphasizing potential therapeutic targets such as CTNNB1, BCL2, TP53, etc, and highlighted ACTB among the top hub genes crucial in disease progression. Drug repurposing on 626 FDA-approved drugs for digestive system-related cancers revealed Norgestimate and Nimesulide as likely top candidates for gastric cancer, validated by molecular docking and dynamics simulations. Further, combinatorial synthesis of scaffold libraries derived from known chemotypes generated 56,160 virtual compounds, of which 76 new compounds were prioritized based on promising binding affinities and interactions at critical residues. Hotspot residue analysis identified GLU 214 and others as essential for ligand binding stability, enhancing compound efficacy and specificity. These findings support the therapeutic potential of targeting beta-actin protein in gastric cancer treatment, suggesting a future for further experimental validation and clinical translation. In conclusion, this study highlights the potential of repurposable drugs and virtual screening which can be used in combination with existing anti-gastric cancer drugs for gastric cancer therapy, emphasizing the role of computational methodologies in drug discovery.
2025-05-01Brain and Behavior
Effective Protection Against Status Epilepticus Caused by Lithium–Pilocarpine: Combination of Midazolam and Lacosamide
Article
作者: Yildirim, Mehmet ; Yildirim, Hava ; Demirtas, Cumaali ; Aykin, Ugur ; Surmeneli, Yunus Emre ; Akca, Metehan
ABSTRACT:
Aim:
Status epilepticus causes the most severe condition related to epilepsy in terms of high mortality rate. Although status epilepticus treatment guidelines specify a treatment process based on three‐stage monotherapy, effective control cannot yet be achieved in all cases. In the presented study, with electrophysiological and behavioral tests, it was aimed to investigate the effectiveness of the combination of midazolam (MDZ), one of the most commonly used benzodiazepines in the first‐line treatment of status epilepticus, with the second‐line antiepileptics levetiracetam (LEV), lacosamide (LCM), valproic acid (VPA), and fosphenytoin (fPHT).
Methods:
A status epilepticus model was created with lithium–pilocarpine (5 mEq/kg–320 mg/kg) in adult male Sprague–Dawley rats with implanted electroencephalography (EEG) electrodes. MDZ (9 mg/kg) alone or in dual combinations with antiepileptic drugs (200 mg/kg LEV, 50 mg/kg LCM, 300 mg/kg VPA, 100 mg/kg fPHT) was injected i.p. to the experiment groups with status epilepticus. After video‐EEG recordings were taken from the rats during and after status, the effects of drug interactions on cognitive and motor behaviors were examined by applying behavioral tests (open field, Rotarod, radial arm maze, and passive avoidance).
Results:
Compared with the untreated status epilepticus group, it was determined that MDZ alone and the combination of four antiepileptic drugs administered with MDZ significantly reduced the mortality rate, spike frequency, and spike amplitude of epileptic seizures and suppressed epileptic seizures at certain levels (p < 0.01). Compared to MDZ monotherapy, it was determined that the mortality rate and spike frequency and amplitude decreased significantly in the MDZ + LCM group (p < 0.01), whereas on the other hand, mortality and spike frequency increased in the MDZ + LEV group (p < 0.01). No negative effects were observed in learning and memory in all treatment groups, but it was determined that the motor functions of the animals treated with MDZ + fPHT were impaired compared to both the control group without any treatment and the MDZ group (p < 0.01).
Conclusion:
In the status epilepticus model induced by lithium–pilocarpine, the combination of MDZ + LCM was found to be the most effective polytherapy option in reducing seizures and mortality. Additionally, it was observed that LEV, LCM, and VPA administered together with MDZ did not negatively affect both cognitive and motor functions.
100 项与 磷苯妥英钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 强直阵挛性癫痫 | 中国 | 2023-03-15 | |
| 癫痫 | 日本 | 2011-07-01 | |
| 癫痫发作 | 美国 | 1996-08-05 | |
| 癫痫持续状态 | 美国 | 1996-08-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性带状疱疹神经病 | 临床3期 | 日本 | 2022-08-05 | |
| 急性疼痛 | 临床3期 | 日本 | 2022-08-05 | |
| 癌症疼痛 | 临床2期 | 日本 | 2019-04-03 | |
| 多发性骨髓瘤 | 临床2期 | 日本 | 2019-04-03 | |
| 神经痛 | 临床2期 | 日本 | 2019-04-03 | |
| 肉瘤 | 临床2期 | 日本 | 2019-04-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 15 | Intravenous fosphenytoin plus oral tapering of phenytoin | 壓艱蓋願獵壓膚襯願範(餘夢鬱築願鏇艱壓構繭) = 窪築憲衊淵選範廠鏇顧 簾鹹鬱淵選鏇獵選憲衊 (齋襯鑰積積簾網艱襯遞 ) | 积极 | 2022-04-25 | ||
临床3期 | 癫痫持续状态 二线 | 462 | (children (aged <18 years)) | 艱窪築艱衊繭鏇遞鬱願(鏇餘醖顧憲積齋築淵鹽) = 鑰鑰襯範簾艱鏇網鹹醖 廠衊憲淵獵築膚範蓋製 (築簾淵鏇願簾窪憲觸鹹, 41 ~ 62) | 积极 | 2020-04-11 | |
(adults) | 艱窪築艱衊繭鏇遞鬱願(鏇餘醖顧憲積齋築淵鹽) = 鏇範選鬱選衊醖餘醖遞 廠衊憲淵獵築膚範蓋製 (築簾淵鏇願簾窪憲觸鹹, 33 ~ 55) | ||||||
临床3期 | 478 | (Fosphenytoin (FOS)) | 鏇顧鏇襯窪艱鹹餘鹽繭 = 觸憲製顧糧淵鹹鹽獵鑰 齋壓觸簾觸製簾憲鏇製 (觸簾齋築窪網築鬱觸窪, 構糧繭窪廠憲構鏇鑰觸 ~ 鹽觸築窪艱觸顧襯顧鏇) 更多 | - | 2020-02-28 | ||
(Valproic Acid) | 鏇顧鏇襯窪艱鹹餘鹽繭 = 遞蓋鏇範衊顧鏇齋齋淵 齋壓觸簾觸製簾憲鏇製 (觸簾齋築窪網築鬱觸窪, 餘壓廠鹽襯蓋壓鬱顧觸 ~ 積鏇艱顧願鑰憲繭繭觸) 更多 | ||||||
临床2期 | 74 | 簾艱積襯願遞獵網積齋 = 願憲醖夢鹹觸壓觸積醖 夢襯鹹蓋窪廠醖鬱積積 (顧壓鹽簾鹽糧鑰醖鏇顧, 鬱觸糧簾衊夢鏇壓積艱 ~ 簾餘衊膚膚範簾鹽壓簾) 更多 | - | 2018-06-11 | |||
临床4期 | 158 | (Phenytoin/Fosphenytoin) | 壓鑰願膚構壓廠夢構簾 = 積鑰範顧衊獵糧窪築醖 夢齋鹹蓋餘壓廠艱構鹹 (窪窪簾襯蓋淵膚繭鹽願, 構製鏇顧憲艱築繭遞夢 ~ 願鏇願觸餘顧艱蓋築艱) 更多 | - | 2013-08-05 | ||
(Levetiracetam) | 壓鑰願膚構壓廠夢構簾 = 鬱艱窪襯選構鏇獵選積 夢齋鹹蓋餘壓廠艱構鹹 (窪窪簾襯蓋淵膚繭鹽願, 鬱夢獵齋醖窪選憲鏇願 ~ 鹽衊艱鑰齋積憲範製積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用